Recommended treatment for OHS patients include: a controlled weight loss program1; and nocturnal positive airway pressure, that is, noninvasive ventilation (NIV).2
Because weight is a major cause of OHS, the first step in treating patients suspected of OHS is weight loss. Losing weight will not only improve their general health, but can also improve alveolar ventilation [PaCO2] and arterial oxygen tension [PaO2].3
As well as following a weight loss program, patients should be monitored through:
arterial blood gases testing
pulmonary function testing
Noninvasive ventilation (NIV)
The main goals of treatment for an OHS patient are to:
prevent erythrocytosis, pulmonary hypertension, and respiratory failure
relieve hypersomnia and altered mentation.
Treatment with NIV achieves these goals and has been widely observed to be the ideal treatment for OHS.2
ResMed’s NIV solution
ResMed’s intelligent Volume-Assured Pressure Support (iVAPS) is a unique technology featured in the LumisTM series and the StellarTM series devices. This new therapy mode adjusts to a patient’s respiratory rate, targets alveolar ventilation and automatically adjusts pressure support as needed to accommodate each patient’s unique needs, even as their disease state progresses.
Adhering to therapy is critical for patients receiving noninvasive ventilation.
Piper JP, Grunstein RR. Obesity hypoventilation syndrome. (2011) Am J Respir Crit Care Med 183:292-298
2: Storre JH, Seuthe B, Fiechter R, Milioglou S, Dreher M, Sorichter S, Windisch W. Average volume-assured pressure support in obesity hypoventilation: A randomised crossover trial. Chest.2006 Sep 130(3): 815-21
3: Zavorsky GS, Hoffman SL. Pulmonary gas exchange in the morbidly obese. Obes Rev 2008 9:326–339